NOVYE PERSPEKTIVNYE PREPARATY DLYa LEChENIYa HER2-POZITIVNOGO RAKA MOLOChNOY ZhELEZY
- Authors: Gorbunova V.A1
-
Affiliations:
- Issue: No 8 (2014)
- Pages: 19-28
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286925
- ID: 286925
Cite item
Open Access
Access granted
Abstract
The article provides an overview of the new advances in drug therapy of HER2-positive breast cancer (BC), which are extremely important next stage of medical oncology. The analysis of studies evaluating the effectiveness of treatment of breast cancer is performed. The data of clinical study comparing the efficacy, safety and pharmacokinetic parameters of trastuzumab for subcutaneous and intravenous administration, as well as studies defining patients’ preferences in choosing these treatment options are presented. The article presents the results of CLEOPATRA trial evaluating the efficacy and safety of the combination of pertuzumab, trastuzumab, and docetaxel as first-line therapy of HER2-positive metastatic breast cancer. The design and methodology of international randomized, open EMILIA trial, evaluating the efficacy and safety of T-DM1 compared with a combination of lapatinib + capecitabine in the second-line treatment of metastatic HER2-positive breast cancer are described in detail.
Full Text
References
- Ismael G., Hegg R., Muehlbauer S., Heinzmann D., et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet. 2012; 13: 869-78.
- Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010; 375: 377-84.
- Untch M., Rezai M., Loibl S., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J. Clin. Oncol. 2010; 28: 2024-31.
- Buzdar A.U., Valero V., Ibrahim N.K., et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin. Cancer Res. 2007; 13: 228-33.
- Dawood S., Gonzalez-Angulo A.M., Peintinger F., et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M.D. Anderson experience. Cancer. 2007; 110: 1195-200.
- Pivot X., Gligorov, Muller V., et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2 positive early breast cancer (PrefHer): an open-label randomised study. www.thelancet.com/oncology Published online August 19, 2013 http://dx.doi.org/10.1016/S1470-2045(13)70383-8
- Swain S.M., Kim, Cortes J., Ro., et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survivalresults from a randomised, double-blind, placebo-controlled, phase 3 study/www.thelancet.com/oncology Published online April 18, 2013 http://dx.doi.org/10.1016/S1470-2045(13)70130-X
- Baselga J., Cortes J., et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N. Engl. J. Med 2012; 366,2: 109-19.
- O'Regan R., Ozguroglu M., Andre F., et al. Phase III, randomized, double-blind, placebocontrolled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumabresistant, advanced breast cancer (BOLERO-3). J. Clin. Oncol. 2013; 31(suppl; abstr 505).
- Verma S.D., Miles, L., Gianni I., et al. Blackwell Updated Overall Survival Results from EMILIA, a phase 3 study of trastuzumab emtansine (T-DM1) vs capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer. ESMO Congress, 2012, abs LBA12.
- Verma S., Miles D., Gianni L., et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N. Engl. J. Med. 2012; 367(19): 1783-91.
- Blackwell K.L., Miles D., Gianni L. et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab and a taxane. J. Clin. Oncol. 2012; 30: (suppl; abstr LBA1).
Supplementary files
